Rapid advances are occurring in multiple sclerosis disease modifying therapies. 
Recent therapeutic advances include modifications to improve tolerability of 
existing products (e.g. interferon beta and glatiramer acetate), development of 
novel anti-neuroinflammatory medications (e.g. fingolimod, teriflunomide and 
dimethyl fumarate, daclizumab, alemtuzumab, ocrelizumab) and investigation of 
treatments in progressive MS (e.g. natalizumab, mastinib, natalizumab, 
siponimod). The impact of vitamin D supplementation on the disease course in 
relapsing MS patients is also being studied in several clinical trials. This 
article reviews the current state of the field with a forward look to the next 
phase of MS research that could focus on strategies to promote remyelination and 
provide neuronal protection.